SR9009
id:
sr9009-300-10339407
title:
SR9009
text:
SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. In an animal study, some of its effects were found to be independent of REV-ERB with an unknown mechanism of action. Activation of Rev-ErbA-α by SR9009 in m
brand slug:
wiki
category slug:
encyclopedia
description:
Chemica compound, Agonist of Rev-ErbA
original url:
https://en.wikipedia.org/wiki/SR9009
date created:
date modified:
2024-03-25T04:15:16Z
main entity:
{"identifier":"Q15410184","url":"https://www.wikidata.org/entity/Q15410184"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/a/a9/SR9009_structure.svg","width":512,"height":323}
fields total:
13
integrity:
15